Anticancer Activity of Annonacin and Its Synergistic Enhancement of Docetaxel Efficacy in Prostate Cancer
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70972 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Yunbei Xiao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Andrology and Sexual Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Docetaxel, Prostatic Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Plan Project of Wenzhou Municipality, Wenzhou Association for Science and Technology.
Abstract (Originalsprache)
Prostate cancer (PCa) is the second most prevalent malignancy in men, and therapeutic options become severely limited once androgen deprivation therapy (ADT) fails. This study evaluated the antitumor activity of Annonacin, a natural acetogenin, alone or in combination with docetaxel (DTX) in PCa. The antitumor effects and underlying mechanisms of Annonacin and/or DTX were investigated in DU145 cells and a xenograft mouse model by assessing proliferation, migration, apoptosis, colony formation, DNA damage and FAK expression and distribution. Through an integrated strategy combining network pharmacology and a series of in vitro assays, the findings demonstrated that Annonacin exerts significant antitumor activity by inducing DNA damage and downregulating FAK expression and localisation. Co‐treatment with DTX further enhanced these effects, with combination index (CI) values < 1, indicating strong synergism. In vivo, the combination therapy achieved more than 74% tumour growth inhibition ( p < 0.0001), accompanied by increased tumour cell death, reduced Ki‐67 expression and elevated γ‐H2AX levels. Collectively, these findings demonstrate that Annonacin exerts potent antitumor activity and synergistically enhances DTX efficacy by promoting DNA damage and suppressing FAK signalling, supporting its potential as a promising adjuvant candidate for PCa treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Andrology and Sexual Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
ORCID-Profile: Yunbei Xiao, Chen Sun, Huiliang Zhou
Förderung
- Science and Technology Plan Project of Wenzhou Municipality
- Wenzhou Association for Science and Technology
Zitieren
APA
Xiao, Y., Wang, Q., Sun, C., Zou, H., Cheng, X., Yao, R., & Zhou, H. (2025). Anticancer Activity of Annonacin and Its Synergistic Enhancement of Docetaxel Efficacy in Prostate Cancer. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70972
Vancouver
Xiao Y, Wang Q, Sun C, Zou H, Cheng X, Yao R, et al. Anticancer Activity of Annonacin and Its Synergistic Enhancement of Docetaxel Efficacy in Prostate Cancer. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70972
BibTeX
@article{Xiao2025,
author = {Xiao, Yunbei and Wang, Qinquan and Sun, Chen and Zou, Haoran and Cheng, Xiaozhi and Yao, Ruijie and Zhou, Huiliang},
title = {Anticancer Activity of Annonacin and Its Synergistic Enhancement of Docetaxel Efficacy in Prostate Cancer},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70972}
}
EUVIMED